Ticlopidine inhibits phenytoin clearance

Clinical Pharmacology and Therapeutics

Volumn 66, Issue 6, 1999, Pages 563-568

  Donahue, Stephen ^b   Flockhart, David A ^b   Abernethy, Darrell R ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; PHENYTOIN; TICLOPIDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; EPILEPSY; HUMAN; LIVER MICROSOME METABOLISM; MICHAELIS CONSTANT; PRIORITY JOURNAL;

EID: 0000723001     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1053/cp.1999.v66.103277001     Document Type: Article

References (18)

1. 1. Desager JP. Clinical pharmacokinetics of ticlopidine. Clin Pharmacokinet 1994;26:347-55.
2. 2. Knudsen JB, Bastain W, Sefton CM, Alien JG, Dickinson JP. Pharmacokinetics of ticlopidine during chronic oral administration to healthy volunteers and its effects on antipyrine pharmacokinetics. Xenobiotica 1992;22:579-89.
3. 3. Shah J, Teitelbaum P, Molony B, Gabuzda T, Massey I. Single and multiple dose pharmacokinetics of ticlopidine in young and elderly subjects. Br J Clin Pharmacol 1991;32:761-4.
4. 4. Colli A, Buccino G, Cocciolo M, Parravicini R, Elli GM, Scaltrini G. Ticlopidine-theophylline interaction. Clin Pharmacol Ther 1987;41:358-62.
5. 5. Giddal BE, Sorkness CA, McGill KA, Larson R, Levine RR. Evaluation of a potential enantioselective interaction between ticlopidine and warfarin in chronically anticoagulated patients. Ther Drug Monit 1995;17:33-8.
6. 6. Levy RH. Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia 1995;36(suppl 5):S8-13.
7. 7. Nation RL, Evans AM, Milne RW. Pharmacokinetic drug interactions with phenytoin (Part I). Clin Pharmacokinet 1990;18:37-60.
8. 8. Klaassen SL. Ticlopidine-induced phenytoin toxicity. Ann Pharmacother 1998;32:1295-8.
9. 9. Lopez-Ariztegui N, Ochoa M, Sanchez-Migallon MJ, Nevado C, Martin M. Acute phenytoin poisoning secondary to an interaction with ticlopidine. Rev Neurol 1998;26:1017-8.
10. 10. Donahue SR, Flockhart DA, Abernethy DR, Ko JW. Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19. Clin Pharmacol Ther 1997;62:572-7.
11. 11. Rindon JP, Bryan G II, Ariz P. Phenytoin toxicity associated with ticlopidine administration. Arch Intern Med 1996;156:1113.
12. 12. Privitera M, Welty TE. Acute phenytoin toxicity followed by seizure breakthrough from a ticlopidine-phenytoin interaction. Arch Neurol 1996;53:1191-2.
13. 13. Riva R, Cerullo A, Albani F, Baruzzi A. Ticlopidine impairs phenytoin clearance: a case report. Neurology 1996;46:1172-3.
14. 14. Richens A. Clinical pharmacokinetics of phenytoin. Clin Pharmacokinet 1979;4:153-69.
15. 15. Christenson RH, Studenberg SD, Beck-Davis S, Sedor FA. Digoxin-like immunoreactivity eliminated from serum by centrifugal ultrafiltration before fluorescence polarization immunoassay of digoxin. Clin Chem 1987:33:606-8.
16. 16. Ludden TM, Allen JP, Valutsky WA, Vicuna AV, Nappi JM, Huffman SF, et al. Individualization of phenytoin dosage regimens. Clin Pharmacol Ther 1977:21:287-93.
17. 17. Bajpai M, Roskos LK, Shen DD, Levy RH. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Dispos 1996;24:1401-3.
18. 18. Wienkers LC, Wurden CJ, Storch E, Kunze KL, Rettie AE, Trager WF. Formation of (R)-8-hydroxywarfarin in human liver microsomes: a new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19. Drug Metab Dispos 1996;24:610-4.